Also noteworthy earlier this month was the publication of a Phase 2 randomized trial in 272 participants without diabetes of orforglipron, an oral GLP-1 agonist, which achieved a 14.7% weight loss (placebo-adjusted 12.3%) at the highest dose With that brief review of the latest trials and drugs, lets turn to clinical outcomes, for which most are taking us back to single agonistGLP-1drugs
Particularly, the arcuate nucleus of the hypothalamus arcuate nucleus (ARC) is critical for appetite regulation and the mechanism of obesity
Injecting too deeply into muscle or too shallowly into the dermis can result in more pain and inconsistent medication absorption
Should the clinical criteria for suspecting glucokinase mutation-related hyperglycemia (MODY-2) be revisited during pregnancy
M., Sevastos, J., Carland, J
Eli Lilly and Company (LLY) on Wednesday said that its oral GLP-1 drug Orforglipron lowered blood glucose levels in two late-stage trials, confirming its potential in treating type-2 diabetes